Altimmune Inc ALT:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 1:07 PM EDT
7.24quote price arrow up+0.05 (+0.70%)
Volume
992,825
52 week range
2.09 - 14.84
Loading...
  • Open7.41
  • Day High7.63
  • Day Low7.23
  • Prev Close7.19
  • 52 Week High14.84
  • 52 Week High Date02/28/24
  • 52 Week Low2.09
  • 52 Week Low Date10/23/23

Key Stats

  • Market Cap513.282M
  • Shares Out70.90M
  • 10 Day Average Volume3.08M
  • Dividend-
  • Dividend Yield-
  • Beta0.09
  • YTD % Change-35.56

KEY STATS

  • Open7.41
  • Day High7.63
  • Day Low7.23
  • Prev Close7.19
  • 52 Week High14.84
  • 52 Week High Date02/28/24
  • 52 Week Low2.09
  • 52 Week Low Date10/23/23
  • Market Cap513.282M
  • Shares Out70.90M
  • 10 Day Average Volume3.08M
  • Dividend-
  • Dividend Yield-
  • Beta0.09
  • YTD % Change-35.56

RATIOS/PROFITABILITY

  • EPS (TTM)-1.64
  • P/E (TTM)-4.40
  • Fwd P/E (NTM)-6.82
  • EBITDA (TTM)-83.033M
  • ROE (TTM)-46.63%
  • Revenue (TTM)425,999.999
  • Gross Margin (TTM)-
  • Net Margin (TTM)-20,762.21%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/09/2024
  • Ex Div Date02/06/2017
  • Div Amount2.91
  • Split Date-
  • Split Factor-

Latest On Altimmune Inc

 

Profile

MORE
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing...
Mitchel Sayare Ph.D.
Independent Chairman of the Board
Vipin Garg Ph.D.
President, Chief Executive Officer, Director
Richard Eisenstadt
Chief Financial Officer
Address
910 Clopper Rd Ste 201S
Gaithersburg, MD
20878-1361
United States

Top Peers

SYMBOLLASTCHG%CHG
KALV
Kalvista Pharmaceuticals Inc
12.07-0.10-0.82%
CELC
Celcuity Inc
17.57-0.09-0.51%
LBPH
Longboard Pharmaceuticals Inc
21.89-0.92-4.03%
NKTX
Nkarta Inc
7.59+0.06+0.80%
THRD
Third Harmonic Bio Inc
11.65+0.06+0.56%